ARCT-810 for OTCD (Phase 2 data 1H '25) must prove IV dosing every 2 weeks is worth better outcomes vs. current treatments; ammonia reduction key measure of success. ARCT-032 for CF (Phase 2 data ...
Wells Fargo analyst Yanan Zhu has maintained their bullish stance on ARCT stock, giving a Buy rating on January 15. Discover outperforming stocks and invest smarter with Top Smart Score Stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback